Welcome to the world of groundbreaking biotechnology research with NewLimit! Led by visionary founder Blake Byers, NewLimit has secured an impressive $40 million in Series A funding from prominent investors such as Coinbase, Founders Fund, Kleiner Perkins, and Dimension. Our mission? Epigenetically reprogramming cells to their younger states, unlocks the potential to restore youthful function in old cells. Through a combination of functional assays, single-cell multi-omics, and cutting-edge machine learning, we dive deep into the epigenetic features of aging and discover rejuvenating interventions.

While our 20-year ambition is to extend the human health span significantly, we are committed to developing intermediary epigenetic reprogramming products for patients suffering from age-related diseases today. By focusing on restoring function in the aging immune system, we aim to revolutionize the treatment landscape for age-related pathologies that have remained elusive. At NewLimit, we embrace inherent optimism, independent thinking, and clear communication as we tackle this moonshot endeavor.